Insider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells 5,401 Shares of Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Nina S. Kjellson sold 5,401 shares of the business’s stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $13.76, for a total value of $74,317.76. Following the completion of the sale, the director now owns 443,885 shares of the company’s stock, valued at $6,107,857.60. The trade was a 1.20 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Tyra Biosciences Trading Down 3.8 %

NASDAQ:TYRA traded down $0.50 during midday trading on Friday, hitting $12.67. 509,563 shares of the company were exchanged, compared to its average volume of 273,199. The company has a fifty day simple moving average of $15.11 and a 200 day simple moving average of $18.81. Tyra Biosciences, Inc. has a fifty-two week low of $12.60 and a fifty-two week high of $29.60. The company has a market capitalization of $641.10 million, a PE ratio of -7.87 and a beta of 1.05.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). As a group, equities research analysts expect that Tyra Biosciences, Inc. will post -1.57 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Bank of America raised shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $22.00 to $31.00 in a research note on Friday, October 18th. Wedbush reissued an “outperform” rating and issued a $28.00 target price on shares of Tyra Biosciences in a research report on Friday, October 25th. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Tyra Biosciences in a research report on Monday, January 13th. Finally, UBS Group assumed coverage on shares of Tyra Biosciences in a report on Tuesday, January 7th. They issued a “buy” rating and a $28.00 price target on the stock. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $30.50.

Institutional Trading of Tyra Biosciences

Institutional investors and hedge funds have recently modified their holdings of the business. US Bancorp DE purchased a new stake in shares of Tyra Biosciences in the fourth quarter valued at about $50,000. China Universal Asset Management Co. Ltd. acquired a new position in Tyra Biosciences during the fourth quarter worth approximately $149,000. Franklin Resources Inc. acquired a new stake in shares of Tyra Biosciences in the third quarter worth $278,000. Valence8 US LP acquired a new stake in shares of Tyra Biosciences in the third quarter worth $310,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Tyra Biosciences in the third quarter worth $311,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.